Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Teresa Shaffer

Nurse Practitioner, Adult Health Boardman, OH Nurse Practitioner

NPI 1770092900 CMS profile 10699566

987 Boardman Canfield Rd, Boardman, OH 44512

Open in the dashboard

General payments

$101,508

460 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Shaffer of Boardman, OH is reported in the CMS Open Payments database as having received $101,508 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,400 132
2024 General $34,198 150
2023 General $36,584 118
2022 General $749 24
2021 General $576 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Shaffer
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Teresa Shaffer were reported at $29,400. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Teresa Shaffer Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $576 $138 $43–$438 $132
2022 $749 $165 $54–$494 $149
2023 $36,584 $178 $61–$549 $160
2024 $34,198 $186 $62–$575 $164
2025 $29,400 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $94,645 199 payments
  2. AbbVie, Inc. $1,821 83 payments
  3. Genzyme Corporation $701 25 payments
  4. E.R. Squibb & Sons, L.L.C. $689 28 payments
  5. Janssen Scientific Affairs, LLC $565 10 payments
  6. Dermavant Sciences, Inc. $371 18 payments
  7. Revance Therapeutics, Inc. $290 6 payments
  8. Incyte Corporation $271 8 payments
  9. Novartis Pharmaceuticals Corporation $263 13 payments
  10. UCB, Inc. $249 11 payments
  11. Other $1,644 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,579 37 payments
  2. Travel and Lodging $21,631 26 payments
  3. Food and Beverage $11,145 388 payments
  4. Consulting Fee $1,600 2 payments
  5. Education $553 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $95,210 209 payments
  2. DUPIXENT $1,012 35 payments
  3. SKYRIZI Immunology $678 39 payments
  4. SOTYKTU $672 27 payments
  5. RINVOQ $580 22 payments
  6. VTAMA $404 20 payments
  7. DAXXIFY $290 6 payments
  8. OPZELURA $271 8 payments
  9. SKYRIZI Immunology $244 13 payments
  10. Bimzelx $231 10 payments
  11. Other $2,126 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

606

Median for Nurse Practitioner: 389

Drug cost

$54,990

Median for Nurse Practitioner: $21,885

Branded share of claims

4.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $42,049
Clobetasol Propionate Generic 119 $4,223
Ketoconazole Generic 127 $2,033
Triamcinolone Acetonide Generic 130 $1,288
Metronidazole Generic 25 $1,079
Fluocinonide Generic 14 $958
Desonide Generic 24 $926
Doxycycline Hyclate Generic 49 $574
Clindamycin Phosphate Generic 11 $402
Imiquimod Generic 15 $390

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$106,806

Of which drugs: $25,097

Medicare patients

428

Average age 73

Services billed

1,517

242 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 32%
Ischemic heart disease 18%
Chronic kidney disease 18%
Depression 17%
Osteoporosis 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 28 39 $11,596

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $31,691
  • Janssen Scientific Affairs, LLC $20
$31,711 — —
DUPIXENT
  • GENZYME CORPORATION $299
  • Regeneron Healthcare Solutions, Inc. $89
$388 11 —
SKYRIZI
  • AbbVie, Inc. $367
$367 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $273
$273 — —
RINVOQ
  • AbbVie, Inc. $208
$208 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record